The GTPase activating factor for transducin in rod photoreceptors is the complex between RGS9 and type 5 G protein β subunit

ELINA R. MAKINO, JASON W. HANDY, TIANSEN LI, AND VADIM Y. ARSHAVSKY*

Department of Ophthalmology, Harvard Medical School, and the Massachusetts Eye and Ear Infirmary, Boston, MA 02114

Communicated by Thaddeus P. Dryja, Harvard Medical School, Boston, MA, December 28, 1998 (received for review December 14, 1998)

ABSTRACT Proteins of the regulators of G protein signaling (RGS) family modulate the duration of intracellular signaling by stimulating the GTPase activity of G protein α **subunits. It has been established that the ninth member of the RGS family (RGS9) participates in accelerating the GTPase activity of the photoreceptor-specific G protein, transducin. This process is essential for timely inactivation of the phototransduction cascade during the recovery from a photoresponse. Here we report that functionally active RGS9 from vertebrate photoreceptors exists as a tight complex with the long splice variant of the G protein** β **subunit (G_{** β **5L}). RGS9 and G**b**5L also form a complex when coexpressed in cell culture. Our data are consistent with the recent observation that several RGS proteins, including RGS9, contain G protein** ^g**-subunit like domain that can mediate their association with G**b**⁵ (Snow, B. E., Krumins, A. M., Brothers, G. M., Lee, S. F., Wall, M. A., Chung, S., Mangion, J., Arya, S., Gilman, A. G. & Siderovski, D. P. (1998)** *Proc. Natl. Acad. Sci. USA* **95, 13307–13312). We report an example of such a complex whose cellular localization and function are clearly defined.**

Heterotrimeric G proteins act as molecular switches that relay excitation from activated receptors to effector molecules, such as enzymes or ion channels. A G protein becomes activated upon the receptor-stimulated binding of GTP to its α subunit and continues to modulate the activity of the effector until bound GTP is hydrolyzed (reviewed in refs. 1 and 2). In many signaling pathways, the duration of the signal under physiological conditions is much shorter than would be predicted from the intrinsic rate of α subunits of G proteins (G_{α}) GTPase activity. This is because GTPase activities of many G_{α} s are dramatically accelerated by RGS (regulators of G protein signaling) proteins or by the G protein effectors (reviewed in refs. 3–6). The phototransduction cascade of vertebrate photoreceptors represents one of the most sophisticated examples of such regulation where the GTPase activity of the G protein, transducin, is substantially enhanced by the cooperative action of RGS9 and the γ subunit of the effector of transducin, cGMP phosphodiesterase (PDE_{γ}) (7–10). The role of RGS9 is to provide transducin with the RGS homology domain, which acts catalytically in stimulating the rate of transducin GTPase. PDE_{γ} itself does not activate transducin GTPase but it enhances the catalytic action of RGS9. The degree of this potentiation observed in physiologically intact photoreceptors is \approx 7-fold (10). We believe that this ability of PDE_y to potentiate RGS9 action is essential for photoreceptor function. When a rod photoreceptor is hit by photon of light it has to perform two tasks. First, it has to transmit the signal from excited rhodopsin to PDE with high efficiency. Second, it has to inactivate all activated proteins in the cascade, including transducin, within a fraction of 1 s. If transducin is allowed to be discharged by RGS9 before it forms a complex with PDE,

PNAS is available online at www.pnas.org.

then some transducin molecules would never activate PDE and signal amplification would be diminished. Therefore, making the GTPase activation contingent on transducin association with PDE_y ensures both high efficiency of signal transmission between transducin and PDE and timely photoresponse recovery.

Although the general scheme for transducin GTPase regulation, outlined above is well supported by experimental data, several fundamental mechanistic questions are not resolved. It remains unclear why the effect of PDE_v observed both with RGS9-containing photoreceptor membranes (7, 8) and intact photoreceptors (10) is substantially more pronounced than its effect in reconstituted system with recombinant catalytic domain of RGS9 (9). It is also not understood why the RGS9 catalytic domain is able to support the rate of transducin GTPase at physiologically fast rate, but intact RGS9 in the photoreceptor requires cooperation with PDE_y . A major difficulty in addressing these questions is that functionally active full-length RGS9 has never been purified or expressed. One possibility is that RGS9 in photoreceptors exists as a multiple subunit complex and that some of its properties could be manifested only within such a complex.

In this study we explored the hypothesis that RGS9 in photoreceptors exists as a multiple subunit complex and found that indeed it is present as a tight complex with the long splice variant of the type 5 β subunit of G proteins (G_{β 5L}) that cannot be separated from RGS9 under nondenaturing conditions. The existence of this complex has been shown by three complimentary approaches. First, RGS9 and $G_{\beta 5L}$ comigrate when photoreceptor membrane proteins were subjected to various chromatographic procedures. Second, antibodies raised against each of these proteins quantitatively precipitated both RGS9 and $G_{\beta 5L}$. Finally, these proteins were coimmunoprecipitated after expression in cell culture.

MATERIALS AND METHODS

Purification and Washing of Rod Outer Segment (ROS) Membranes. ROS were purified from frozen retinas (TA & WL Lowson, Lincoln, NE) under IR illumination as described (11). To obtain membranes lacking most peripheral proteins but retaining an active $RGS9-G_{\beta 5L}$ complex, ROS were washed under IR illumination twice with isotonic buffer containing 100 mM KCl, 2 mM MgCl_2 , 1 mM DTT, and 10 mM Tris^{HCl} (pH 7.5) and three times by a hypotonic buffer containing 0.5 mM EDTA and 5 mM Tris \cdot HCl (pH 7.5). Urea-washed photoreceptor discs lacking the activity of RGS9 were obtained as described (12). Rhodopsin concentration in

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''*advertisement*'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: RGS, regulators of G protein signaling; G_{α} , α subunits of G proteins; G_{β} , β subunits of G proteins; G_{γ} , γ subunits of G proteins; ROS, rod outer segments; PDE, type 6 cGMP phosphodiesterase from ROS; PDE_{γ}, the γ subunit of PDE; GGL domain, G protein γ subunit-like domain; GAP, GTPase activating protein; $G_{\beta 5L}$, long splice variant of G_{β} .

^{*}To whom reprint requests should be addressed at: Howe Laboratory/ Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston MA 02114. e-mail: varshavsky@meei.harvard.edu.

all membrane preparations was determined spectrophotometrically (13).

Preparation of Proteins. Transducin was purified from ROS as described (14). The only modification was that we bleached rhodopsin in the retinas before ROS purification to increase transducin yield by forming a tight complex between bleached rhodopsin and transducin, thus preventing transducin loss from ROS membranes during ROS isolation. Transducin concentration was first estimated by the Bradford assay (15), and then the exact concentration of active transducin in each preparation was determined by measuring the maximal amount of rhodopsin-catalyzed guanosine 5^{\prime} [γ -thio]triphosphase (GTP[γ S]) binding (16).

Recombinant PDE_y was purified by a combination of cationexchange and reverse-phase chromatography (17) from *Escherichia coli* strain BL21 DE3 transformed with an expression plasmid containing a cDNA encoding PDE_{γ} (18). The PDE_{γ} concentration was determined spectrophotometrically at 280 nm by using a molar extinction coefficient of 7,100.

GTPase Measurements. Transducin GTPase activity was determined by the single-turnover ($[GTP] <$ [transducin]) technique described in detail previously (7, 19, 20). The measurements were conducted at room temperature (22– 24° C) in a buffer containing 10 mM Tris \cdot HCl (pH 7.8), 100 mM NaCl, 8 mM MgCl₂, and 1 mM DTT. The urea-treated photoreceptor discs used as a source of rhodopsin were bleached on ice immediately before the experiments. For measuring the activity in the gel-filtration chromatography fractions, 10 μ l of the fraction was mixed with 10 μ l of the test system containing 20 μ M rhodopsin and 2 μ M transducin with or without 2 μ M PDE_{γ} (all concentrations final). The reaction was started by adding 5 μ l of [γ -³²P]GTP (\approx 10⁵ dpm/sample) and conducted for 5 s. The reaction was stopped by the addition of 100 μ l of 6% perchloric acid. ³²P_i formation was measured by the activated charcoal binding assay (20).

Antibody Production and Protein Immunoprecipitation. Sheep antibodies were produced by Elmira Biologicals (Iowa City, IA) against $G_{\beta 5L}$ peptides DKCFKQRALRPVFKKS (N-terminal peptide, NTL), TLRVSPDGTAFCS (C-terminal peptide, CT), and MATDGLHENETLASLK (N terminus of the $G_{\beta 5}$ short splice variant, NT_S). Each of the peptides contained an additional cysteine residue at the N terminus. Sheep antibodies were also produced against the His-tagged RGS9 fragment 226–484 called RGS9c by He *et al.* (9). The pET14b plasmid encoding the His-tagged RGS9c was a gift from T. G. Wensel (Baylor College of Medicine, Houston, TX). Rabbit antibodies were produced against the His-tagged RGS9c and $G_{\beta 5L}$ N-terminal peptide. Rabbit anti-RGS9c antibodies used in some experiments were a gift from T. G. Wensel. Rabbit NT_S antibodies were a gift from V. Z. Slepak (University of Miami). Each antibody was affinity purified on columns where antigens were covalently attached to SulfoLink medium (Pierce) according to instructions provided by Pierce. These antibodies were used for a standard Western blot analysis by using Amersham ECL kit for developing. No cross-reactivity with other ROS proteins on Western blots was observed with any of the affinity-purified antibodies. Some of the purified antibodies were also used for protein immunoprecipitation assays. In these cases antibodies were covalently attached to AminoLink medium (Pierce) according to instructions provided by Pierce. Five milligrams of the antibodies was attached to 1 ml of the beads. Pre-immune IgG were used as controls. All immunoprecipitation assays were performed in 200 μ l of PBS buffer containing 0.5% lauryl sucrose. Fifty microliters of AminoLink beads was typically used in the assay. The samples were incubated for 2.5 h at room temperature upon mixing on the vortex shaker. The beads were separated from the supernatant by a brief centrifugation and washed twice with the same buffer. Bound proteins were extracted from the beads by 1-min boiling in the standard sample buffer for SDS/PAGE. Antibodies against $G_{\gamma2}$ were obtained from Santa Cruz Biotechnology.

Mass Spectrometric Fingerprinting. Mass spectrometric fingerprinting analysis was performed by J. Lee at the Molecular Biology Core Facilities at the Dana–Farber Cancer Institute (Boston). Protein mixtures were subjected to SDS/PAGE, gels were stained by Coomassie blue G-250 (Sigma), and bands containing proteins of interest were cut from the gel and proteolyzed by trypsin as described (21). The molecular masses of proteolytic peptide fragments were determined by MALDI-TOF (matrix-assisted laser desorption ionization-time of flight) spectrometry on Voyager-DE STR instrument (Perceptive Biosystems, Cambridge, MA). The values for molecular masses in digests were compared with the values from theoretical digests by using PROTEINPROSPECTOR MS-Fit software (available via internet at http://prospector.ucsf.edu). The probability of the positive protein identification was assessed with the molecular weight search score described (22). Because the amount of protein in the bands originated from the gel filtration fractions was too small to obtain reliable data, we performed the analysis with the $G_{\beta 5L}$ immunoreactive band obtained from the concentrated alkaline extract of washed ROS membranes. The extraction was performed as described (23) by 100 mM Na₂CO₃ with the pH adjusted to 12.0 by NaOH. Before the SDS/PAGE separation, proteins in the extract were concentrated by precipitation with 3% trichloroacetic acid.

cDNA Cloning and *in Vitro* **Expression.** A mouse retinal cDNA library (provided by D. Roof, Harvard Medical School) was screened with a rat RGS9 cDNA probe (24) provided by M. Koelle (Yale University). Among 10 positive clones, 1 contained the complete coding sequence as concluded by its comparison with the published mouse RGS9 sequence (9). The mouse $G_{\beta 5L}$ cDNA containing a point mutation that inactivates an alternative downstream translational initiation site (25) was provided by V. Z. Slepak. The bovine $G_{\gamma 2}$ cDNA cloned in the expression vector pEV1 (26) was provided by Dr. A. Pronin (T. Jefferson University, Philadelphia).

For *in vitro* expression, the mouse RGS9 and $G_{\beta 5L}$ coding regions were subcloned into the mammalian expression vector pcDNA3 (Invitrogen). The purified expression plasmids were transfected either singly or in combination into the HEK293 cell line by using the LipofectAmine Plus reagent (Life Technologies, Gaithersburg, MD) following the manufacturer's protocols. Cells were harvested 48 hr posttransfection, and their membranes were purified as described (27).

RESULTS AND DISCUSSION

Comigration of RGS9 and Gb**5L upon Gel Filtration of ROS Membrane Proteins.** Our strategy in identifying ROS proteins that potentially associate with RGS9 was to look for proteins that comigrate with both RGS9 and the GTPase activating protein (GAP) activity upon chromatographic separation of solubilized ROS membranes. ROS membranes were washed as described in *Materials and Methods* to minimize the total amount of non-rhodopsin protein bands (but retaining RGS9) in the starting material. A nonionic detergent, lauryl sucrose, was used for membrane solubilization because we have found that it does not substantially influence the basal rate of transducin GTPase activity or the ability of RGS9 to stimulate this activity in the PDE_y -dependent manner at concentrations $< 0.25\%$ (data not shown). Thus, this choice of detergent provided us with an advantage to analyze the GAP activity of RGS9 directly in the chromatography fractions.

Gel filtration of solubilized washed membranes on the Superose-6 column is illustrated in Fig. 1*A*. The ability of the fractions to stimulate transducin GTPase in a PDE_{γ}dependent manner (Fig. 1*B*) correlated with the presence of the RGS9 band (Fig. 1*C*). The only other band whose density profile precisely followed the activity profile was the band with

FIG. 1. Comigration of RGS9 and G_{B5L} during gel filtration. Washed ROS membranes (containing 3 mg rhodopsin) were solubilized in 400 μ l of buffer (20 mM Hepes adjusted to pH 7.4 by KOH, 100 mM NaCl, 2 mM MgCl2, 1 mM DTT, and 2% lauryl sucrose) and loaded on the Superose 6 column attached to the fast protein liquid chromatography (FPLC) system (Pharmacia). The column was equilibrated by the same buffer containing 0.5% lauryl sucrose, 5% glycerol, and 2 mg/ml soybean $L-\alpha$ -phosphatidylcholine (Sigma product P-5638). The elution rate was 0.4 mlymin; the fraction size was 0.4 ml. (*A*) Protein elution profile monitored at 280 nm. The major source of the UV absorbance is rhodopsin. (*B*) GAP activity of RGS9 in chromatography fractions. Single-turnover transducin GTPase measurements were performed in duplicate with and without PDE_Y (see *Materials and Methods*). The *y*-axis value represents the percentage of GTP hydrolysis over the 5-s period; error bars indicate the range of determined values. The St.m bars represent the activity in the starting material after it was diluted to achieve the same lauryl sucrose, glycerol, and phosphatidylcholine concentration as in the fractions. (*C*) Coomassie staining of proteins in fractions surrounding the peak of RGS9 activity. (*D*) Western blot immunostaining of the 44-kDa protein band by three immune and pre-immune serums raised in sheep against the GB5L C-terminal peptide (CT), $G_{\beta 5L}$ N-terminal peptide (NT_L), and N-terminal peptide of the $G_{\beta 5}$ short splice variant (NT_S). (*E*) Comigration of RGS9 and $G_{\beta 5L}$ in the chromatography fractions. Western blots were probed with rabbit anti-RGS9c and anti-NTs antibodies.

an apparent molecular mass of 44 kDa (Fig. 1*C*). This molecular mass corresponds to that of $G_{\beta 5L}$ (43,566 Da in mouse), which was previously reported to be a ROS-specific, membrane-associated protein of unknown function (25). To test the hypothesis that the 44-kDa protein is $G_{\beta 5L}$, we generated three different antibodies against peptides from various regions of $G_{\beta 5L}$, including the N-terminal sequence which is absent in the $G_{\beta 5}$ short splice variant. Fig. 1*D* shows that all three antibodies provided strong immunostaining of the 44-kDa band on Western blots. The data from Fig. 1*E*, where both RGS9 and $G_{\beta5L}$ are immunostained by corresponding antibodies, provide clear evidence that these proteins comigrate during the gel filtration.

Mass spectrometric fingerprinting analysis was used to obtain an independent confirmation that the 44-kDa protein is G_{B5L} (see *Materials and Methods* for details). Nineteen major peptides were identified in the tryptic digest of the putative $G_{\beta5L}$ band. Protein database search analysis indicated that 10 peptides in the digest potentially originate from mouse $G_{\beta 5L}$ with the molecular weight search (MOWSE) score of 70,500. Because the amino acid sequence of bovine $G_{\beta 5}$ is not currently known, this score should be considered as the lowest estimate.

The MOWSE score for the next most likely candidate among all known sequenced mammalian proteins was only 601 (human carboxylesterase hCE-2). Another way to stress the uniqueness of the $G_{\beta 5L}$ identification is to note that not a single sequenced mammalian protein with molecular mass between 40 and 50 kDa could contribute more than three of the 19 peptides to this digest (assuming the same stringency of the search parameters).

RGS9 and Gb**5L Could Not Be Separated upon Ion Exchange Chromatography and Immunoprecipitation by Specific Antibodies.** Our first approach to demonstrate that RGS9 and $G_{\beta 5L}$ indeed form a tight complex in ROS was to show that these proteins comigrate upon various chromatographic separations of the ROS membrane proteins. As seen clearly in Fig. 2, a precise comigration of these proteins is observed when solubilized ROS membranes were subjected to both cation exchange chromatography on Mono-S column and anion exchange chromatography on Mono-Q column. We did not observe any chromatography fractions where either protein was present alone or where RGS9 and $G_{\beta 5L}$ relative abundance was noticeably mismatched.

Our second approach to establish the existence of the RGS9– $G_{\beta 5L}$ complex was to show that both of these proteins

FIG. 2. Comigration of RGS9 and GB5L during cation-exchange and anion-exchange chromatography. Washed ROS membranes (containing 3 mg rhodopsin) were solubilized in 500 μ l of 2% lauryl sucrose either in 20 mM Hepes-KOH (pH 6.0) with 2 mM MgCl₂ (MonoS) or in 50 mM Tris HCl (pH 7.8) with 2 mM MgCl₂ (MonoQ). The columns were equilibrated by the corresponding buffers containing 0.5% lauryl sucrose. A 0–1 M gradient of NaCl was used to elute the bound proteins. The flow rate was 1 ml/min; the fraction size was 1 ml. Western blots of the chromatography fractions were probed by a mixture of rabbit anti-RGS9c and anti-NT_S antibodies against G_{B5} at dilutions yielding similar intensities of immunostaining. No GAP activity in corresponding fractions was present in these cases, consistent with previous reports that this activity is extremely unstable in detergent solutions (32).

could be immunoprecipitated by antibodies raised against each individual protein. As reported by Cowan *et al.* (23), polyclonal antibodies raised against the RGS9c domain have an ability to interact with RGS9 in its native conformation and to deplete its GAP activity from solubilized membranes. A similar observation for the anti-RGS9c antibodies obtained in our study is illustrated in Fig. 3*A*. RGS9 precipitation was also accompanied by a practically complete precipitation of $G_{\beta 5L}$. No precipitation of either protein was observed with control pre-immune IgG. Similarly, an antibody against the N-terminal domain of $G_{\beta 5L}$ quantitatively precipitated both $G_{\beta 5L}$ and RGS9 (Fig. 3*B*). Consistently with the data by Cowan *et al.* (23), the precipitation of RGS9 by either antibody resulted in the depletion of the PDE_{γ} -stimulated GAP activity for transducin from the solubilized ROS membranes (data not shown).

The data from Figs. 1–3 thus provide independent evidence that RGS9 exists as a tight complex with $G_{\beta 5L}$ in photoreceptors and that neither protein exists in any significant amount free from the other.

RGS9 and Gb**5L Form a Complex upon Their Expression in the HEK293 Cells.** The data from Fig. 4 indicate that RGS9 and $G_{\beta 5L}$ also form a complex after being coexpressed in human embryonic kidney cells, HEK293. When RGS9 cDNA was expressed alone, anti-RGS9c antibodies immunoprecipitated the entire pool of RGS9 from the membrane fraction of HEK293 cells. As expected, when $G_{\beta 5L}$ was expressed in the absence of RGS9 it was not precipitated by the same antibodies. However, when RGS9 and $G_{\beta 5L}$ were coexpressed, a substantial fraction of $G_{\beta 5L}$ was precipitated. In spite of the fact that the ability of expressed proteins to form complex was preserved, no detectable GAP activity of RGS9 was observed in these experiments. We coexpressed $G_{\beta 5L}$ with $G_{\gamma 2}$ because this resulted in a significant increase in the levels of $G_{\beta 5L}$ expression, as reported by others (28, 29). This led to the observation illustrated in Fig. 4*C*. $G_{\gamma2}$ was completely absent from the $G_{\beta 5L}$ fraction precipitated by the anti-RGS9 antibodies. Instead, the entire pool of $G_{\gamma2}$ was found in the $G_{\beta 5L}$ fraction that did not contain RGS9. These data suggest that $G_{\beta 5L}$ binding to RGS9 occurs as an alternative to the $G_{\beta 5L}$ binding to $\tilde{G}_{\gamma 2}$. This finding is consistent with the idea that RGS9 contains the G protein γ subunit-like domain (GGL domain), which should make it possible for $G_{\beta5}$ to form a complex with RGS9 instead of forming a complex with a G_{γ} (30). Interestingly, we did not observe coprecipitation of $G_{\beta 5L}$ with $G_{\gamma2}$ by the NT_L anti- $G_{\beta 5L}$ antibodies, in spite of the fact that the level of G_{β 5L} expression with G_{γ 2} was significantly higher than without $G_{\gamma 2}$. This is similar to the lack of $G_{\beta 5}$ coprecipitation with $G_{\gamma2}$ in COS-7 cells reported by Snow *et al.* (30). This apparent discrepancy between the ability of $G_{\gamma2}$ to enhance $G_{\beta 5}$ expression and the lack of their coimmunoprecipitation might be explained if the $G_{\beta 5}-G_{\gamma 2}$ is of low affinity, or if their association is transient, but necessary for the proper $G_{\beta 5}$ processing.

Consistent with the idea that RGS9 substitutes G_{γ} in the complex with G_{β 5L}, we failed to identify any G_y within the

FIG. 3. Reciprocal coimmunoprecipitation of RGS9 and G_{B5L} by rabbit anti-RGS9c (*A*) and anti-G_{B5L} NT_L (*B*) antibodies. Washed ROS membranes, containing either 180 (*A*) or 8 (*B*) μ g rhodopsin, were solubilized in 0.5% lauryl sucrose and subjected to the immunoprecipitation. The difference in the amounts of membranes used in *A* and *B* reflects \approx 20-fold difference in precipitating capacities of the antibodies used in the assay. Western blots from the samples originated from the starting material (St.m), unbound proteins in the supernatant (S) and proteins bound to the pelleted beads (P) were probed with purified sheep anti-RGS9c and anti-NT_s antibodies.

 $RGS9-G_{\beta5L}$ complex obtained from ROS membranes. This result is evident from three lines of experiments. (*i*)The mass spectrometric fingerprinting analysis of the alkaline protein extract from washed ROS membranes was performed for the entire area of the SDS/PAGE gels where all known $G_{\gamma}s$ could be found (between the dye front and the 14-kDa molecular mass standard). It revealed a strong signal for $G_{\gamma1}$ and no hint for any other known G_{γ} . Further analysis with the G_{γ} -specific antibodies (by both chromatography and immunoprecipitation) has indicated that $G_{\gamma1}$ is found only in fractions containing the β subunit of transducin, G_{β 1}, but not in the G_{β 5L} fractions. (*ii*)Immunostaining of both gel-filtration fractions

FIG. 4. Coimmunoprecipitation of RGS9 and $G_{\beta 5L}$ expressed in the HEK293 cells. HEK293 cells were transfected with pcDNA3- RGS9 plasmid, pcDNA3-G $_{\beta 5L}$ and pEV1-G_{γ 2} plasmids, or all three plasmids. Membranes from each transfected line were solubilized in 0.5% lauryl sucrose and immunoprecipitated with rabbit anti-RGS9c antibodies. Three identical Western blots were performed with the aliquots of unbound proteins in the supernatant (S) and proteins bound to the pelleted beads (P). Each blot was probed with one of three antibodies: purified sheep anti-RGS9c (*A*)**,** purified sheep anti-G_{β 5L} NT_S antibodies (*B*), and commercial rabbit anti-G_{γ 2} antibodies (*C*).

and RGS9– $G_{\beta 5L}$ immunoprecipitates by all commercially available antibodies against G_γ ($G_{\gamma1}$, $G_{\gamma2}$, $G_{\gamma3}$, $G_{\gamma5}$, and $G_{\gamma7}$) provided negative results. (*iii*) The sample from the RGS9– $G_{\beta 5L}$ immunoprecipitate did not produce a detectable band on the SDS/PAGE gel in the area where a transducin sample with similar amount of $G_{\beta1}$ produced a clear staining of $G_{\gamma1}$ (data not shown).

The Ability to Form Complexes with $G_{\beta 5}$ Is a General **Property of Several RGS Proteins.** The observations presented in this study are consistent with the data from two recent publications obtained with RGS proteins other than RGS9. Snow *et al.* (30) have found that RGS11 contains the GGL domain which enables it to form a complex with both short and long splice variants of $G_{\beta5}$ upon their coexpression in cell culture. This interaction is highly specific, and no other known type of G protein β subunit, besides G_{β 5}, can interact with RGS11. Similar domains are present in RGS6, RGS7, RGS9 and *Caenorhabditis elegans* protein EGL-10 (30). They have also observed that the RGS11– $G_{\beta5}$ complex has a GAP activity with an unusually high selectivity toward the α subunit of the G protein, Go. In another study by Cabrera *et al.* (31), a short splice variant of $G_{\beta 5}$ was copurified with RGS7 from the retinal extract depleted of ROS, indicating that they might be present as a complex.

Taken together, these studies challenge one of the central paradigms in G protein signaling. It is generally accepted that G_{β} s always function as tight complexes with G_{γ} s. However, it is now clear that $G_{\beta 5}$ is capable of forming complexes with RGS proteins instead of binding to a G_{γ} . Our experiments provide an example of such a complex whose cellular localization and physiological function are clearly defined. The RGS9– $G_{\beta 5L}$ complex is responsible for activating transducin GTPase in photoreceptor outer segments, and it does this in a cooperative interaction with the effector of transducin, PDE_y . The challenge for future experiments is to define the role of each individual protein subunit in this task.

We thank Drs. M. D. Bownds, A. Bohm, C. L. Makino, M. Sokolov, and P. D. Calvert for critically reading the manuscript, and Mr. M. Goulston for technical assistance. This work was supported by National Institutes of Health Grant EY 10336, a grant from the Massachusetts Lions Eye Research Fund, and a Jules and Doris Stein Professorship from Research to Prevent Blindness (to V.Y.A.). T.L. is a recipient of a Career Development Award from Research to Prevent Blindness.

- 1. Neer, E. J. (1995) *Cell* **80,** 249–257.
- 2. Hildebrandt, J. D. (1997) *Biochem. Pharmacol.* **54,** 325–339.
- 3. Koelle, M. R. (1997) *Curr. Opin. Cell Biol.* **9,** 143–147.
- 4. Dohlman, H. G. & Thorner, J. (1997) *J. Biol. Chem.* **272,** 3871–3874.
- 5. Berman, D. M. & Gilman, A. G. (1998) *J. Biol. Chem.* **273,** 1269–1272.
- 6. Arshavsky, V. Y. & Pugh, E. N. (1998) *Neuron* **20,** 11–14.
- 7. Angleson, J. K. & Wensel, T. G. (1994) *J. Biol. Chem.* **269,** 16290–16296.
- 8. Arshavsky, V. Y., Dumke, C. L., Zhu, Y., Artemyev, N. O., Skiba, N. P., Hamm, H. E. & Bownds, M. D. (1994) *J. Biol. Chem.* **269,** 19882–19887.
- 9. He, W., Cowan, C. W. & Wensel, T. G. (1998) *Neuron* **20,** 95–102.
- 10. Tsang, S. H., Burns, M. E., Calvert, P. D., Gouras, P., Baylor, D. A., Goff, S. P. & Arshavsky, V. Y. (1998) *Science* **282,** 117–121.
- 11. McDowell, J. H. (1993) *Methods Neurosci.* **15,** 123–130.
- 12. Nekrasova, E. R., Berman, D. M., Rustandi, R. R., Hamm, H. E., Gilman, A. G. & Arshavsky, V. Y. (1997) *Biochemistry* **36,** 7638–7643.
- 13. Bownds, M. D., Gordon-Walker, A., Gaide-Huguenin, A.-C. & Robinson, W. (1971) *J. Gen. Physiol.* **58,** 225–237.
- 14. Ting, T. D., Goldin, S. B. & Ho, Y.-K. (1993) *Methods Neurosci.* **15,** 180–195.
- 15. Bradford, M. M. (1976) *Anal. Biochem.* **72,** 248–254.
- 16. Fung, B. B.-K., Hurley, J. B. & Stryer, L. (1981) *Proc. Natl. Acad. Sci. USA* **78,** 152–156.
- 17. Brown, R. L. & Stryer, L. (1989) *Proc. Natl. Acad. Sci. USA* **86,** 4922–4926.
- 18. Slepak, V. Z., Artemyev, N. O., Zhu, Y., Dumke, C. L., Sabacan,

L., Sondek, J., Hamm, H. E., Bownds, M. D. & Arshavsky, V. Y. (1995) *J. Biol. Chem.* **270,** 14319–14324.

- 19. Arshavsky, V. Y., Antoch, M. P., Lukjanov, K. A. & Philippov, P. P. (1989) *FEBS Lett.* **250,** 353–356.
- 20. Arshavsky, V. Y., Gray-Keller, M. P. & Bownds, M. D. (1991) *J. Biol. Chem.* **266,** 18530–18537.
- 21. Shevchenko, A., Wilm, M., Vorm, O. & Mann, M. (1996) *Anal. Chem.* **68,** 850–858.
- 22. Pappin, D. J. C., Hojrup, P. & Bleasby, A. J. (1993) *Curr. Biol.* **3,** 327–332.
- 23. Cowan, C. W., Fariss, R. N., Sokal, I., Palczewski K. & Wensel, T. G. (1998) *Proc. Natl. Acad. Sci. USA* **95,** 5351–5356.
- 24. Koelle, M. R. & Horvitz, H. R. (1996) *Cell* **84,** 115–125.
- 25. Watson, A. J., Aragay, A. M., Slepak, V. Z. & Simon, M. I. (1996) *J. Biol. Chem.* **271,** 28154–28160.
- 26. Pronin, A. N. & Gautam, N. (1992) *Proc. Natl. Acad. Sci. USA* **89,** 6220–6224.
- 27. Nathans, J., Weitz, C. J., Agarwal, N., Nir, I. & Papermaster, D. S. (1989) *Vision Res.* **29,** 907–914.
- 28. Watson, A. J., Katz, A. & Simon, M. I. (1994) *J. Biol. Chem.* **269,** 22150–22156.
- 29. Zhang, S., Coso, O. A., Lee, C., Gutkind, J. S. & Simonds, W. F. (1996) *J. Biol. Chem.* **271,** 33575–33579.
- 30. Snow, B. E., Krumins, A. M., Brothers, G. M., Lee, S. F., Wall, M. A., Chung, S., Mangion, J., Arya, S., Gilman, A. G. & Siderovski, D. P. (1998) *Proc. Natl. Acad. Sci. USA* **95,** 13307–13312.
- 31. Cabrera, J. L., De Freitas, F., Satpaev, D. K. & Slepak, V. Z. (1998*) Biochem. Biophys. Res. Commun.* **249**, 898–902.
- 32. Cowan, C. W., Angleson, J. K. & Wensel, T. G. (1996) *Invest. Ophthalmol. Vis. Sci.* **37,** S809.